Vyriad

Vyriad is a clinical-stage biotech company founded in 2016 in the United States. The company specializes in developing targeted genetic therapies that deliver genes directly to cells. Vyriad engineers viruses, viral vectors, and viral envelope glycoproteins to enable the delivery of genes to targeted cells, facilitating oncolytic virotherapy, in vivo gene therapies, and gene editing applications. The company is actively conducting Phase 1-2 Clinical Studies for various cancer types including non-small cell lung cancer, squamous cell carcinoma of the head and neck, metastatic colorectal cancer, breast cancer, bladder cancer, and others. Vyriad's clinical research collaborations with Regeneron, Mayo Clinic, and other leading research and medical institutions reinforce its position in the biotechnology industry. Vyriad recently secured a notable $29.50M Series B investment on 17 May 2022. The investors contributing to this round include Mirae Asset, Mayo Clinic, Southeast Minnesota Capital Fund, Regeneron, and Harry H. Stine. This significant investment indicates growing confidence in Vyriad's innovative approach to genetic therapies and reflects its potential for further development and impact in the biotechnology sector.